AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “buy” rating reissued by analysts at Jefferies Group LLC in a research report issued on Wednesday. They currently have a $40.00 target price on the specialty pharmaceutical company’s stock, down from their previous target price of $45.00. Jefferies Group LLC’s target price points to a potential upside of 65.29% from the stock’s previous close.

A number of other research firms also recently commented on AMAG. Cantor Fitzgerald began coverage on shares of AMAG Pharmaceuticals in a report on Thursday, December 15th. They issued a “neutral” rating and a $33.00 price objective for the company. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 9th. Raymond James Financial, Inc. reaffirmed an “underperform” rating on shares of AMAG Pharmaceuticals in a report on Monday, January 9th. Janney Montgomery Scott started coverage on shares of AMAG Pharmaceuticals in a report on Tuesday, January 3rd. They set a “buy” rating and a $45.00 price target for the company. Finally, Needham & Company LLC started coverage on shares of AMAG Pharmaceuticals in a report on Wednesday, October 26th. They set a “buy” rating and a $40.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Hold” and an average target price of $31.20.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 24.20 on Wednesday. The stock’s market capitalization is $828.95 million. The firm’s 50-day moving average is $25.36 and its 200 day moving average is $27.06. AMAG Pharmaceuticals has a 12-month low of $17.92 and a 12-month high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Tuesday, February 14th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of $1.85 by $2.16. The business earned $151.60 million during the quarter, compared to analyst estimates of $155.12 million. AMAG Pharmaceuticals had a return on equity of 11.10% and a net margin of 3.12%. The business’s revenue for the quarter was up 39.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.12 EPS. Equities research analysts anticipate that AMAG Pharmaceuticals will post $6.00 earnings per share for the current year.

“AMAG Pharmaceuticals, Inc. (AMAG) Rating Reiterated by Jefferies Group LLC” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this report can be viewed at http://www.watchlistnews.com/amag-pharmaceuticals-inc-amag-rating-reiterated-by-jefferies-group-llc/1121633.html.

Institutional investors have recently made changes to their positions in the stock. Falcon Point Capital LLC increased its position in shares of AMAG Pharmaceuticals by 23.8% in the third quarter. Falcon Point Capital LLC now owns 881,026 shares of the specialty pharmaceutical company’s stock valued at $22,642,000 after buying an additional 169,254 shares during the period. LSV Asset Management increased its position in shares of AMAG Pharmaceuticals by 41.1% in the third quarter. LSV Asset Management now owns 379,337 shares of the specialty pharmaceutical company’s stock valued at $9,297,000 after buying an additional 110,500 shares during the period. BlackRock Fund Advisors increased its position in shares of AMAG Pharmaceuticals by 5.5% in the third quarter. BlackRock Fund Advisors now owns 3,164,395 shares of the specialty pharmaceutical company’s stock valued at $77,559,000 after buying an additional 163,791 shares during the period. Clark Estates Inc. NY increased its position in shares of AMAG Pharmaceuticals by 17.0% in the third quarter. Clark Estates Inc. NY now owns 103,100 shares of the specialty pharmaceutical company’s stock valued at $2,527,000 after buying an additional 15,000 shares during the period. Finally, Credit Capital Investments LLC increased its position in shares of AMAG Pharmaceuticals by 268.3% in the third quarter. Credit Capital Investments LLC now owns 109,813 shares of the specialty pharmaceutical company’s stock valued at $2,691,000 after buying an additional 80,000 shares during the period.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

5 Day Chart for NASDAQ:AMAG

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.